China
· Delayed Price · Currency is CNY Tianjin Pharmaceutical Da Ren Tang Group Corporation Statistics
Total Valuation
Tianjin Pharmaceutical Da Ren Tang Group Corporation has a market cap or net worth of CNY 23.16 billion. The enterprise value is 20.77 billion.
| Market Cap | 23.16B |
| Enterprise Value | 20.77B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Tianjin Pharmaceutical Da Ren Tang Group Corporation has 770.16 million shares outstanding. The number of shares has decreased by -0.39% in one year.
| Shares Outstanding | 770.16M |
| Shares Change (YoY) | -0.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.70% |
| Owned by Institutions (%) | 6.08% |
| Float | 418.21M |
Valuation Ratios
The trailing PE ratio is 29.10 and the forward PE ratio is 23.23.
| PE Ratio | 29.10 |
| Forward PE | 23.23 |
| PS Ratio | 3.31 |
| PB Ratio | 4.26 |
| P/FCF Ratio | 26.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.47, with an EV/FCF ratio of 20.60.
| EV / Earnings | 22.53 |
| EV / Sales | 2.56 |
| EV / EBITDA | 22.47 |
| EV / EBIT | 25.99 |
| EV / FCF | 20.60 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.56 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.16 |
| Debt / FCF | 1.06 |
| Interest Coverage | 21.75 |
Financial Efficiency
Return on equity (ROE) is 14.26% and return on invested capital (ROIC) is 6.85%.
| Return on Equity (ROE) | 14.26% |
| Return on Assets (ROA) | 4.49% |
| Return on Capital (ROIC) | 6.85% |
| Revenue Per Employee | 1.75M |
| Profits Per Employee | 199,596 |
| Employee Count | 4,619 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.14% in the last 52 weeks. The beta is 0.76, so Tianjin Pharmaceutical Da Ren Tang Group Corporation's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +6.14% |
| 50-Day Moving Average | 30.36 |
| 200-Day Moving Average | 31.93 |
| Relative Strength Index (RSI) | 67.74 |
| Average Volume (20 Days) | 6,475,354 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of CNY 8.10 billion and earned 921.94 million in profits. Earnings per share was 1.19.
| Revenue | 8.10B |
| Gross Profit | 3.64B |
| Operating Income | 799.06M |
| Pretax Income | 1.03B |
| Net Income | 921.94M |
| EBITDA | 919.90M |
| EBIT | 799.06M |
| Earnings Per Share (EPS) | 1.19 |
Balance Sheet
The company has 3.51 billion in cash and 1.07 billion in debt, giving a net cash position of 2.43 billion or 3.16 per share.
| Cash & Cash Equivalents | 3.51B |
| Total Debt | 1.07B |
| Net Cash | 2.43B |
| Net Cash Per Share | 3.16 |
| Equity (Book Value) | 6.31B |
| Book Value Per Share | 8.14 |
| Working Capital | 2.92B |
Cash Flow
In the last 12 months, operating cash flow was 1.12 billion and capital expenditures -113.14 million, giving a free cash flow of 1.01 billion.
| Operating Cash Flow | 1.12B |
| Capital Expenditures | -113.14M |
| Free Cash Flow | 1.01B |
| FCF Per Share | 1.31 |
Margins
Gross margin is 44.99%, with operating and profit margins of 9.87% and 11.38%.
| Gross Margin | 44.99% |
| Operating Margin | 9.87% |
| Pretax Margin | 12.77% |
| Profit Margin | 11.38% |
| EBITDA Margin | 11.36% |
| EBIT Margin | 9.87% |
| FCF Margin | 12.45% |
Dividends & Yields
This stock pays an annual dividend of 1.28, which amounts to a dividend yield of 3.59%.
| Dividend Per Share | 1.28 |
| Dividend Yield | 3.59% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 2.42% |
| Buyback Yield | 0.39% |
| Shareholder Yield | 3.98% |
| Earnings Yield | 3.44% |
| FCF Yield | 3.77% |
Stock Splits
The last stock split was on July 5, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Jul 5, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Tianjin Pharmaceutical Da Ren Tang Group Corporation has an Altman Z-Score of 4.1.
| Altman Z-Score | 4.1 |
| Piotroski F-Score | n/a |